 |
26 Diseases |  |
58 Trials |
|
58 Trials |  |
4692 News |  |
| «12...7891011121314151617...6263» |
- Vocabria (cabotegravir oral) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Subjective sleep quality evolution in patients starting or switching to dolutegravir or cabotegravir: a real-world longitudinal study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_757;
Besides dolutegravir (DTG), also bictegravir and cabotegravir (CBG) have been introduced in clinical practice...Only a minority of patients switched from an efavirenz-containing regimen (n=4) (Table 1)...The proportion of patients with poor sleep quality remains however high. The smaller cohort size may have hampered unmasking more subtle differences.
- IMPACT OF DIFFERENT ANTIRETROVIRAL DRUGS ON ADIPOCYTE DIFFERENTIATION (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_756;
The smaller cohort size may have hampered unmasking more subtle differences. Purpose :
- IMPACT OF DIFFERENT ANTIRETROVIRAL DRUGS ON ADIPOCYTE DIFFERENTIATION (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_755;
Purpose : Purpose :
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Tenofovir plasma and intracellular pharmacokinetics IN Insti-based regimens (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_752;
Role of adherence to ART, not different by group, has no impact on virosuppression or PK parameters in our population. Further studies are warranted.
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Tenofovir plasma and intracellular pharmacokinetics IN Insti-based regimens (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_751;
Role of adherence to ART, not different by group, has no impact on virosuppression or PK parameters in our population. Further studies are warranted.
- Tivicay (dolutegravir) / ViiV Healthcare
Impact of pre-existing HIV-1 primary and secondary reverse transcriptase and integrase resistance-associated mutations by next generation sequencing on virological response to dolutegravir (DTG)-containing regimens in antiretroviral-na (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_716;
Resistance analyses in the 9 subjects with VF did not reveal any emergent resistance to the study drugs. Analyses of virological outcomes at weeks 48 and 96 did not find a significant role of pre-existing resistance in any of the analyzed groups (Fig.2) Conclusions :
- Tivicay (dolutegravir) / ViiV Healthcare
Impact of pre-existing HIV-1 primary and secondary reverse transcriptase and integrase resistance-associated mutations by next generation sequencing on virological response to dolutegravir (DTG)-containing regimens in antiretroviral-na (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_715;
Resistance analyses in the 9 subjects with VF did not reveal any emergent resistance to the study drugs. Analyses of virological outcomes at weeks 48 and 96 did not find a significant role of pre-existing resistance in any of the analyzed groups (Fig.2) Conclusions :
- Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Real-world data on the use of the antiretroviral treatment (ART) regimen tenofovir alafenamide/emtricitabine/darunavir/cobicistat (TAF/FTC/DRV/c) and dolutegravir (DTG) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_708;
Analyses of virological outcomes at weeks 48 and 96 did not find a significant role of pre-existing resistance in any of the analyzed groups (Fig.2) Conclusions : Results :
- Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Real-world data on the use of the antiretroviral treatment (ART) regimen tenofovir alafenamide/emtricitabine/darunavir/cobicistat (TAF/FTC/DRV/c) and dolutegravir (DTG) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_707;
Results : Results :
- Drug resistance mutations conferring resistance to integrase inhibitors among HIV patients in Tel Aviv, between 2010-2020, prevalence and risk factors (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_698;
68% of participants who showed resistance were treated with first-generation drugs (Raltegravir, Elvitegravir). Among participants who did not show resistance, 84.3% were treated with second-generation drugs (dolutegravir, Bictegravir)...Conclusions :
- Drug resistance mutations conferring resistance to integrase inhibitors among HIV patients in Tel Aviv, between 2010-2020, prevalence and risk factors (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_697;
68% of participants who showed resistance were treated with first-generation drugs (Raltegravir, Elvitegravir). Among participants who did not show resistance, 84.3% were treated with second-generation drugs (dolutegravir, Bictegravir)...Conclusions :
- Tivicay (dolutegravir) / ViiV Healthcare
No Relevant Difference in Incident Hypertension Observed by Gender, Race, Baseline BMI, or Other Key Subgroups Through Week 96 Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_632;
Among participants who did not show resistance, 84.3% were treated with second-generation drugs (dolutegravir, Bictegravir)...Conclusions : Conclusions :
- Tivicay (dolutegravir) / ViiV Healthcare
No Relevant Difference in Incident Hypertension Observed by Gender, Race, Baseline BMI, or Other Key Subgroups Through Week 96 Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_631;
Conclusions : Conclusions :
- Tivicay (dolutegravir) / ViiV Healthcare
Durability of two-drug antiretroviral regimens as maintenance therapy in people living with HIV and reasons for switch to a three-drug regimen: a real-life cohort study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_572;
Dolutegravir (DTG) or ritonavir-boosted protease inhibitor (PI/r) based 2DR were the most prescribed regimens respectively in 63% and 17% of cases...Drug reduction and side effects were the main reasons for switching. Use of newly recommended 2DR could improve 2DR durability in the future.
- Tivicay (dolutegravir) / ViiV Healthcare
Durability of two-drug antiretroviral regimens as maintenance therapy in people living with HIV and reasons for switch to a three-drug regimen: a real-life cohort study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_571;
Dolutegravir (DTG) or ritonavir-boosted protease inhibitor (PI/r) based 2DR were the most prescribed regimens respectively in 63% and 17% of cases...Drug reduction and side effects were the main reasons for switching. Use of newly recommended 2DR could improve 2DR durability in the future.
- Tivicay (dolutegravir) / ViiV Healthcare
DOLAM-500: Efficacy and safety of Dolutegravir (DTG) plus Lamivudine (3TC) in ART-naive PLWH with baseline viral load ?500.000 copies/ml (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_536;
Use of newly recommended 2DR could improve 2DR durability in the future. Purpose :
- Tivicay (dolutegravir) / ViiV Healthcare
DOLAM-500: Efficacy and safety of Dolutegravir (DTG) plus Lamivudine (3TC) in ART-naive PLWH with baseline viral load ?500.000 copies/ml (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_535;
Purpose : Purpose :
- Tivicay (dolutegravir) / ViiV Healthcare
Effectiveness and safety of a generic formulation of dolutegravir in clinical practice in a Latin American cohort: 18-month real-world data (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_478;
Accompanying NRTIs were predominantly 3TC/TDF (73.8% and 48.6% in naive and experienced patients, respectively) and 3TC (9.5% and 32.3%, respectively). Conclusions :
- Tivicay (dolutegravir) / ViiV Healthcare
Effectiveness and safety of a generic formulation of dolutegravir in clinical practice in a Latin American cohort: 18-month real-world data (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_477;
Accompanying NRTIs were predominantly 3TC/TDF (73.8% and 48.6% in naive and experienced patients, respectively) and 3TC (9.5% and 32.3%, respectively). Conclusions :
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Bictegravir versus Dolutegravir-based three-drug regimen in the setting of Rapid ART Initiation (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_474;
Lower chance of virological suppression by week 48 in BIC-group was confounded by high basal viremia. Indeed, high viral load at baseline was associated with a higher risk of treatment failure.
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Bictegravir versus Dolutegravir-based three-drug regimen in the setting of Rapid ART Initiation (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_473;
Lower chance of virological suppression by week 48 in BIC-group was confounded by high basal viremia. Indeed, high viral load at baseline was associated with a higher risk of treatment failure.
- Pifeltro (doravirine) / Merck (MSD), Tivicay (dolutegravir) / ViiV Healthcare
DoDo: Real Life Experience with an Alternative Antiretroviral 2-Drug Regimen of Doravirine and Dolutegravir (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_471;
Indeed, high viral load at baseline was associated with a higher risk of treatment failure. Purpose :
- Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD), Tivicay (dolutegravir) / ViiV Healthcare
Real-world 2-year weight changes among people with sustained HIV suppression : A multicenter French retrospective cohort study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_470;
Exposure to Doravirine-based antiretroviral combination (Figure 2) was significantly associated with lower weight change (-2.6 kg, p=0.02) than other combinations, after adjusting for PRIORLINES and baseline weight. Conclusions :
- Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD), Tivicay (dolutegravir) / ViiV Healthcare
Real-world 2-year weight changes among people with sustained HIV suppression : A multicenter French retrospective cohort study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_469;
Exposure to Doravirine-based antiretroviral combination (Figure 2) was significantly associated with lower weight change (-2.6 kg, p=0.02) than other combinations, after adjusting for PRIORLINES and baseline weight. Conclusions :
- Intermittent three-drug regimens (i-3DR) as maintenance ART: a meta-analysis including individual participant data (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_462;
The breakdown of VF cases by antiretroviral class is depicted in the forest plot (Figure 1) for second generation (G) INSTI (Dolutegravir or Bictegravir, INSTI-2G); INSTI-1G (Raltegravir or Elvitegravir); NNRTI-1G (Efavirenz or Rilpivirine); NNRTI-2G (Etravirine or Doravirine) and boosted protease inhibitor (Darunavir, Lopinavir, Atazanavir) with significant heterogeneity overall (I-squared, 53%, p<0.01). Conclusions :
- Intermittent three-drug regimens (i-3DR) as maintenance ART: a meta-analysis including individual participant data (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_461;
The breakdown of VF cases by antiretroviral class is depicted in the forest plot (Figure 1) for second generation (G) INSTI (Dolutegravir or Bictegravir, INSTI-2G); INSTI-1G (Raltegravir or Elvitegravir); NNRTI-1G (Efavirenz or Rilpivirine); NNRTI-2G (Etravirine or Doravirine) and boosted protease inhibitor (Darunavir, Lopinavir, Atazanavir) with significant heterogeneity overall (I-squared, 53%, p<0.01). Conclusions :
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Cardiovascular disease prevalence in a cohort of HIV positive (PLWH) patients, over 50 years of age, in the era of the INSTI based regimen: a proof of concept retrospective analysis (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_438;
Previous exposure to INSTI was frequent but does not seem correlated with a higher risk. More in-depth analysis is ongoing on a larger cohort.
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Cardiovascular disease prevalence in a cohort of HIV positive (PLWH) patients, over 50 years of age, in the era of the INSTI based regimen: a proof of concept retrospective analysis (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_437;
Previous exposure to INSTI was frequent but does not seem correlated with a higher risk. More in-depth analysis is ongoing on a larger cohort.
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Bictegravir and Dolutegravir influence leukocytes and/or platelets in a way that promotes a proinflammatory milieu which favors cardiovascular toxicity (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_432;
This study evaluates how leukocytes and platelets are influenced by three of the most widely employed INSTIs [dolutegravir (DTG), bictegravir (BIC), raltegravir (RAL)], and compares their actions with those of a NRTI (abacavir; ABC) known to produce CV toxicity and a NNRTI (doravirine, DOR), both of which were used as controls. Conclusions :
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Bictegravir and Dolutegravir influence leukocytes and/or platelets in a way that promotes a proinflammatory milieu which favors cardiovascular toxicity (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_431;
This study evaluates how leukocytes and platelets are influenced by three of the most widely employed INSTIs [dolutegravir (DTG), bictegravir (BIC), raltegravir (RAL)], and compares their actions with those of a NRTI (abacavir; ABC) known to produce CV toxicity and a NNRTI (doravirine, DOR), both of which were used as controls. Conclusions :
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Virologic Response Following a Switch to Dolutegravir-based Regimen in People Living with HIV/AIDS at a Tertiary Care Center in Nepal. (Pubmed Central) - Oct 5, 2023
Method This is a retrospective cohort study including people living with human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS) who were transitioned to Tenofovir/Lamivudine/Dolutegravir previously on other antiretroviral therapy regimens for at least 6 months and who had their viral load test done before transition...Tenofovir/Lamivudine/Efavirenz (47.4%), Zidovudine/ Lamivudine/Nevirapine (22.8%) and Zidovudine/Lamivudine/Efavirenz (17.5%) were the most common antiretroviral regimens before transition...Following the transition, 96.5% of the patients had suppressed viral load of fewer than 40 copies/mL. Conclusion Dolutegravir-based antiretroviral regimen led to untransmittable viral load following a switch from Nevirapine and Efavirenz-based regimen.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens. (Pubmed Central) - Oct 5, 2023
The findings support the use of dolutegravir-based regimens in the treatment of patients with HIV-associated neurocognitive disorders. HIV-associated neurocognitive disorders; BNCE; IHDS; dolutegravir; neurocognitive screening; neurocognitive impairment; South Africa.
- | Journal: Risks of metabolic syndrome in the ADVANCE and NAMSAL trials. (Pubmed Central) - Oct 4, 2023
In this analysis, we highlight treatment-emergent metabolic syndrome associated with dolutegravir, likely driven by obesity. Clinicians initiating or monitoring patients on INSTI-based ART must counsel for lifestyle optimisation to prevent these effects.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical data, Retrospective data, Journal: Clinical outcomes after extended 12-month antiretroviral therapy prescriptions in a community-based differentiated HIV service delivery programme in South Africa: a retrospective cohort study. (Pubmed Central) - Oct 4, 2023
Among PLHIV referred for community ART with a recent suppressed VL, the use of 12M scripts reduced clinic visits without impacting short-term clinical outcomes. 12M scripts should be considered for differentiated service delivery programmes.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial. (Pubmed Central) - Oct 4, 2023
Plasma and RBC folate levels were higher in children and adolescents receiving dolutegravir-based ART than on other ART regimens. Further studies are needed to clarify the mechanisms of these interactions and the clinical implications of increased blood folate levels.
- || Tivicay (dolutegravir) / ViiV Healthcare
Review, Journal: Treatment Emergent Dolutegravir Resistance Mutations in Individuals Na (Pubmed Central) - Oct 2, 2023
Further studies are needed to clarify the mechanisms of these interactions and the clinical implications of increased blood folate levels. Among INSTI-na
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Na (Pubmed Central) - Oct 2, 2023
Among INSTI-na HIVDR to DTG is rare among ART na
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Rapid fabrication of hydrophobic/hydrophilic patterns on paper substrates for paper spray mass spectrometry. (Pubmed Central) - Oct 2, 2023
In a proof-of-concept experiment, calibration curves were generated for each antiretroviral in urine. A patterned paper substrate with a 2-mm channel resulted in an average 7.4-fold improvement in sensitivity and an average 18-fold improvement in limits of detection over uncoated paper substrates.
- | Journal: HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial. (Pubmed Central) - Sep 27, 2023
P4
Six adverse events were recorded during our study, which did not cause any withdrawal from the study. We observed a decrease in HIV-DNA from baseline to W48 in PLWH treated during PHI, associated with an increase in CD4+ count, unrelated to the treatment arm.
- || Tivicay (dolutegravir) / ViiV Healthcare
PK/PD data, Journal: Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents. (Pubmed Central) - Sep 26, 2023
Observed pharmacokinetic variability was higher in this pediatric population and no additional safety concerns were observed. These results support the weight-banded dosing of dolutegravir in pediatric participants currently recommended by the World Health Organization.
- | Aptivus (tipranavir) / Boehringer Ingelheim, Fetroja (cefiderocol) / Shionogi, Tivicay (dolutegravir) / ViiV Healthcare
FDA event, Journal: In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs. (Pubmed Central) - Sep 26, 2023
We identified four potential inhibitors namely, Tipranavir, Cefiderocol, Doxorubicin, and Dolutegravir as candidates for repurposing against monkeypox virus from a library of US FDA approved antiviral and antibiotic drugs using molecular docking and molecular dynamics simulations. The main goal of this in silico study is to identify potential inhibitors against monkeypox virus proteins that can be further experimentally validated for the discovery of novel therapeutic agents against monkeypox disease.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy. (Pubmed Central) - Sep 26, 2023
Among PLHIV receiving ART, a rapid urine TFV immunoassay can be used to accurately monitor urine TFV levels compared to the gold standard of LC-MS/MS. Undetectable point-of-care urine TFV results were associated with viraemia, particularly among people receiving dolutegravir.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. (Pubmed Central) - Sep 25, 2023
These differences should be interpreted with caution in an open-label trial. Clinicians and policy makers should consider including suicidality screening of children or adolescents receiving dolutegravir.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini. (Pubmed Central) - Sep 18, 2023
Birth defect surveillance in Eswatini in 2020-2021 identified 0.80% defects (197/24 599 live and stillborn infants). Neural tube defect (NTD) prevalence was 0.08%, 0.08%, and 0.15% for 4902 women on dolutegravir preconception, 17 285 HIV-negative women, and 1320 women on efavirenz preconception, respectively, more definitively refuting the dolutegravir preconception NTD safety signal.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Development and validation of an HPLC method for quantification of dolutegravir in human plasma. (Pubmed Central) - Sep 18, 2023
Neural tube defect (NTD) prevalence was 0.08%, 0.08%, and 0.15% for 4902 women on dolutegravir preconception, 17 285 HIV-negative women, and 1320 women on efavirenz preconception, respectively, more definitively refuting the dolutegravir preconception NTD safety signal. The linearity of DTG was good in the range of 0.05-10??g/mL (r
- | Tivicay (dolutegravir) / ViiV Healthcare
Preclinical, Journal: Folate deficiency increases the incidence of dolutegravir-associated foetal defects in a mouse pregnancy model. (Pubmed Central) - Sep 18, 2023
Maternal folate deficiency may increase the risk for DTG-associated foetal defects. Periconceptional folic acid supplementation could be considered for women with HIV taking DTG during pregnancy, particularly in countries lacking folate fortification programs.
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare
Trial primary completion date, Head-to-Head: D3 (Penta21): DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children with HIV Infection Aged 2 to <15 Years Old (clinicaltrials.gov) - Sep 18, 2023
P2/3, N=370, Recruiting, Sponsor: PENTA Foundation
Periconceptional folic acid supplementation could be considered for women with HIV taking DTG during pregnancy, particularly in countries lacking folate fortification programs. Trial primary completion date: Oct 2023 --> Sep 2024
- ||||| Tivicay (dolutegravir) / ViiV Healthcare, GSK3640254 / ViiV Healthcare
Trial termination, Combination therapy: DYNAMIC: A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults (clinicaltrials.gov) - Sep 13, 2023
P2b, N=85, Terminated, Sponsor: ViiV Healthcare
The decision was not based on any safety or efficacy concerns. It reflected the company strategy for portfolio progression.
- ||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Trial termination: Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE) (clinicaltrials.gov) - Sep 13, 2023
P3, N=100, Terminated, Sponsor: Ospedale San Raffaele
Unknown status --> Terminated; The futility analysis on 24-week results estimated that there was only 2% probability of verifying the study hypothesis of a higher proportion pat. with no residual viremia through 48w in arm E/C/F/TAF
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: Woddol4455: Women in Dual With Dolutegravir (clinicaltrials.gov) - Sep 13, 2023
P3, N=290, Not yet recruiting, Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
with no residual viremia through 48w in arm E/C/F/TAF Initiation date: Mar 2023 --> Oct 2023